You are leaving the BesinsPro site. This link will take you to a website where our Privacy Policy does not apply.
Besins Healthcare UK Ltd. has no control over the contents of these sites or resources and accepts no responsibility for them or for any loss or damage that may arise from your use of them.


MAT-PROMO-NP-0156 December 2025

You are leaving the BesinsPro site. This link will take you to a website to where our Privacy Policy does not apply.
Besins Healthcare UK Ltd. has no control over the contents of these sites or resources and accepts no responsibility for them or for any loss or damage that may arise from your use of them.


MAT-PROMO-NP-0156 December 2025

You are currently leaving this website.

thumbnail_header_1_9b4e82e6d4_1db369c5a3.png

own_it_transparent_106687c6e6.png

Menopause symptoms

symptoms_desktop_improved_57c891f107_6a58d775b4.png

thumbnail_7_5a2134e455.png

thumbnail_8_c802b051fa.png

Problems with concentration/memory

thumbnail_9_95d72500be.png

thumbnail_11_caa08b0b9e.png

thumbnail_12_e8be6e4d68.png

race_and_menopause_desktop_f8b15a5582_1_0ba80395bb.png

BMS: Women’s experience of menopause in Great Britain Survey Fact Sheet. 2016. Available at:

House of Commons Women and Equalities Committee Menopause and the workplace survey results Fourth Special Report of Session 2021–22

NHS Inform. Signs and symptoms of menopause.

Bauld R, Brown RF. Maturitas. 2009;62(2):160-5;

Viotti S, et al. Int J Environ Res Public Health. 2021;18(19):10029;

NHS Inform. Menopause.

Women’s Health Concern. Weight gain and menopause.

British Menopause Society. Menopause in ethnic minority women. 

Martin MC, et al. Am J Obstet Gynecol. 1993;168(6 Pt 1):1839-43.

Harlow SD, et al. Women’s Midlife Health. 2022;8:3.

Kono S, et al. Maturitas 1990;12:43–49.

Qazi RA, et al. J Coll Physicians Surg Pak. 2006;16(11):700–3.

Kriplani A, et al. Maturitas. 2005;52:199–204.

Wise J. BMJ. 2022 Feb 14;376:o382.

Menopause Symptoms

Explore our resources on hormone health, designed for UK healthcare professionals. Access therapy area and product information, on-demand educational content, and updates on upcoming events.

A dedicated hub for UK healthcare professionals only. Access product information, clinical resources, and educational content across women’s and men’s hormone health.

BesinsPro UK | Healthcare Professional Hub for Women’s & Men’s Health

Besins UK Hub homepage

Explore our range of products at Besins Healthcare UK Ltd

Explore Besins Healthcare products, including treatments for menopause and testosterone deficiency. For UK healthcare professionals only.

Products | BesinsPro UK

Products

Explore resources to share with your patients on Besins products and different therapy areas.

Patient Resources

Use the details below to report an adverse event to Besins Healthcare UK.

Adverse Event Reporting | Report an adverse event to Besins Healthcare UK.

Adverse Event Reporting

Fill out the form below to contact our team.

Submit an enquiry	

Get in touch with Besins Healthcare UK for medical information, product enquiries, or support. For UK healthcare professionals only.

Contact Us | BesinsPro UK

Contact us

Explore resources for HCPs on Besins products and different therapy areas.

HCP resources

The UK’s first and only licensed progesterone treatment for the prevention of miscarriage in women with a history of recurrent miscarriage who present with bleeding in the first trimester.¹

Prometrium homepage

This area offers streamlined access to essential product information and clinical data. This page includes future and upcoming webinars as well as materials to support you in your practice. 

Prometrium educational resources

Find out how you can provide guidance for your patients on the UK’s first and only licensed progesterone treatment for the prevention of miscarriage in women with a history of recurrent miscarriage who present with bleeding in the first trimester.¹
These resources are to be used with your patients who have been prescribed Prometrium.

Prometrium Patient support items

For HCPs, by HCPs. Our podcast series puts HCP voices in the spotlight, bringing you practical advice on everyday challenges in delivering patient care in hormone health.

Podcasts

Explore HCP webinars and events on hormone health from Besins Healthcare UK.

Webinars and events

Discover information on dosing and administration for the UK’s first and only licensed progesterone treatment for the prevention of miscarriage in women with a history of recurrent miscarriage who present with bleeding in the first trimester.¹

Prometrium dosing and administration

Understand the clinical trial data supporting the efficacy of 400mg vaginal progesterone for the prevention of miscarriage in women with a history of recurrent miscarriage who present with bleeding in the first trimester.¹

Prometrium efficacy  

Learn about the safety profile of the UK’s first and only licensed progesterone treatment for the prevention of miscarriage in women with a history of recurrent miscarriage who present with bleeding in the first trimester.¹

Prometrium safety information

Prometrium FAQ

We are committed to protecting your personal data and to respecting your privacy.

Cookie Policy

Coming soon

Privacy Policy

These online terms of use (“Terms of Use”) govern the access of the user (“you”) to websites (“our website(s)”) controlled by Besins Healthcare (UK) Ltd.

Terms of Use

Terms of use

Empower her to manage her menopause

Oestrogel® (estradiol 0.06% w/w) 



A preferred treatment choice2

For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used.3
<ul>
<li>This medicine contains 0.5g alcohol (ethanol) in each dose of 1.25g gel3</li>
<li>Do not apply to damaged skin3</li>
<li>This product is flammable until dry3</li>
<li>Patients should be informed that children should not come in contact with the area of the body where Oestrogel was applied on due to the transfer risk. Post-marketing reports of breast development and sexual changes following unintentional secondary exposure have been reported. In most cases, the condition resolved with removal of estradiol exposure.3</li>
<li>For the treatment of postmenopausal symptoms, HRT should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually, and HRT should only be continued as long as the benefit outweighs the risk3</li>
</ul>

Please refer to the Summary of Product Characteristics for more information on adverse effects including risk of venous thromboembolism, breast cancer and stroke. HRT should only be continued as long as the benefit outweighs the risk.3

Dosing for menopausal and postmenopausal symptoms2

For first use – setting up the pump pack 11

Set up your Oestrogel Pump-Pack

Consider transdermal Oestrogel for your eligible postmenopausal patients for VMS control and Utrogestan® (micronised progesterone) 100mg to greatly reduce the oestrogen-induced risk of endometrial hyperplasia in non-hysterectomised women.3,6,10,12

Does your patient have a uterus?

A tailored dosing schedule3

Oestrogel

Empower her to own her menopause

Oestrogel® (estradiol 0.06% w/w) efficacy


Adverse events (>10%) reported over a 12-week period

The most common adverse events were headache (18.1%), breast pain (10.4%), infection (10.0%), pain (7.7%), nausea (7.2%), rash (5.4%) and vaginitis (5.4%).3Oestrogel was effective and generally well tolerated for alleviating moderate-to-severe hot flushes in postmenopausal women.3

were very/fairly satisfied with ease of use

were very/fairly satisfied with how well Oestrogel fits into their daily life

were very/fairly satisfied with how effective Oestrogel is in reducing their menopause symptoms

In a survey (organised and funded by Besins Healthcare UK) we asked Oestrogel patients (N=156) how satisfied they were with the following features of the Oestrogel pump-pack:4

Preference satisfaction data for Oestrogel patients4

Oestrogel Efficacy

Oestrogel® (estradiol 0.06% w/w) safety information

Frequency of occurrence of Adverse Drug Reactions

The information given in the table above is based on frequency of occurrence of adverse drug reactions for estradiol. 


Please refer to the Summary of Product Characteristics (SmPC) for more information on adverse events, including risk of venous thromboembolism, breast cancer and stroke. Hormone replacement therapy (HRT) should only be continued as long as the benefit outweighs the risk.
 

Do not apply to damaged skin.
 

This product is flammable until dry.
 

Patients should be informed that children should not come in contact with the area of the body where Oestrogel was applied on due to the transfer risk. Post-marketing reports of breast development and sexual changes following unintentional secondary exposure have been reported. In most cases, the condition resolved with removal of estradiol exposure.

Oestrogel Safety

We have compiled responses to patient queries to help the women in your care feel informed, confident and ready to ‘Own it’.

FAQs and support tools

Oestrogel Support

Utrogestan® 100mg (micronised progesterone)

The addition of progesterone greatly reduces the oestrogen-induced risk of endometrial hyperplasia in non-hysterectomised women. 

Utrogestan Home

Utrogestan® 100mg (micronised progesterone) efficacy

Treatment regimen

Adapted from Lindenfeld 2002 et al. Data on endometrial histology outcomes across treatment arms. *Includes 30 cases in which the diagnosis was assigned by the local gynaecologist because the local, central and artbiter pathologists gave different options. 

†P=.16 (normal vs abnormal) for placebo compared with CEE + MPA (cyc), CEE + MPA (con), and CEE + MP. ‡P<.001 for placebo compared with CEE only.

Endometrial biopsy changes since baseline*4

Adapted from Lindenfeld 2002 et al. *Contrast with CEE + MP (here and following): P ≤.001.

Length and episodes of bleeding by treatment for women with at least 80% adherence3

Utrogestan Efficacy

is generally well tolerated1

Utrogestan  100mg (micronised progesterone) is generally well tolerated

The information given below is based on extensive post marketing experience, from oral administration of progesterone. 

Utrogestan Safety

Ensure the women in your care get the most from their treatment

Utrogestan Support

This website has been developed and funded by Besins Healthcare (UK) Ltd. and is intended for UK HCP's only.

MAARS Toolkit Resource Page

This is a promotional webinar, recorded in September 2025. This webinar features two leaders in early pregnancy care sharing practical learning on developing nurse‑led early pregnancy and recurrent miscarriage services. 

The full webinar has been divided into a series of short, topic-specific videos, providing UK healthcare professionals with practical perspectives on delivering early pregnancy care. Information correct at the time of recording

Prometrium Resource Page

This promotional webinar is intended for UK healthcare professionals involved in fertility and early pregnancy care.


This webinar will explore the role of progesterone across the patient pathway, from luteal phase support in IVF through to the management of early pregnancy complications in a wider patient population.

Prometrium webinar sign up 

Burden of menopause 

80% of menopausal women experience menopausal signs and symptoms3

20% of women experience severe menopausal symptoms.3

of women find at least one menopause symptom very difficult.5

of women experience three or more severe symptoms.5

Menopause symptoms

How menopause symptoms impact women’s daily lives¹

Burden of symptoms experienced by women in their day-to-day lives

Burden of symptoms experienced by women at work

Race and menopause

References

Menopause symptoms

How menopause symptoms impact women’s daily lives1

Burden of symptoms experienced by women in their day-to-day lives

Burden of symptoms experienced by women at work

Race and menopause

References

How menopause symptoms impact women’s daily lives¹